New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
10:00 EDTAIG, ARG, WLH, URBN, TOL, SNTA, PHM, NWBO, MSI, LVNTA, HRZN, FRX, DRH, CHD, ABC, AEO, AMRE, GERNOn The Fly: Analyst Downgrade Summary
AIG (AIG) downgraded to Hold from Buy at Deutsche Bank... AmREIT (AMRE) downgraded to Hold from Buy at Jefferies... American Eagle (AEO) downgraded to Underweight from Equal Weight at Morgan Stanley... AmerisourceBergen (ABC) downgraded to Neutral from Buy at Goldman... Church & Dwight (CHD) downgraded to Neutral from Outperform at Credit Suisse... Clean Harbors (CLH) downgraded to Outperform from Top Pick at RBC Capital... DiamondRock (DRH) downgraded to Underperform from Neutral at BofA/Merrill... Forest Labs (FRX) downgraded to Neutral from Overweight at Piper Jaffray... Horizon Technology (HRZN) downgraded to Underperform at Keefe Bruyette... Liberty Ventures (LVNTA) downgraded to Neutral from Buy at Citigroup... Motorola Solutions (MSI) downgraded to Sell from Neutral at Goldman... Northwest Biotherapeutics (NWBO) downgraded to Perform from Outperform at Oppenheimer... PulteGroup (PHM) downgraded to Neutral from Outperform at Credit Suisse... Synta Pharmaceuticals (SNTA) downgraded to Underperform from Market Perform at BMO Capital... Toll Brothers (TOL) downgraded to Neutral from Outperform at Credit Suisse... Urban Outfitters (URBN) downgraded to Equal Weight from Overweight at Barclays... William Lyon Homes (WLH) downgraded to Neutral from Outperform at Credit Suisse... Airgas (ARG) downgraded to Hold from Buy at BGC Financial... Geron (GERN) downgraded to Neutral from Overweight at Piper Jaffray.
News For AIG;AMRE;AEO;ABC;CHD;DRH;FRX;HRZN;LVNTA;MSI;NWBO;PHM;SNTA;TOL;URBN;WLH;ARG;GERN From The Last 14 Days
Check below for free stories on AIG;AMRE;AEO;ABC;CHD;DRH;FRX;HRZN;LVNTA;MSI;NWBO;PHM;SNTA;TOL;URBN;WLH;ARG;GERN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2014
07:35 EDTARGAirgas reports Q1 EPS $1.18, consensus $1.18
Subscribe for More Information
07:35 EDTARGAirgas sees Q2 EPS $1.27-$1.32, consensus $1.32
Subscribe for More Information
07:35 EDTARGAirgas reiterates FY15 EPS view $5.00-$5.20, consensus $5.10
Full year guidance includes a negative $0.11 to $0.16 per diluted share year-over-year impact from variable compensation reset following a below-budget year in fiscal 2014. The Company currently expects the contribution from its refrigerants business to year-over-year earnings per diluted share growth in fiscal 2015 to be slightly favorable.
07:03 EDTABCAmerisourceBergen now sees FY14 adjusted continuing ops EPS $3.89-$3.94
Consensus is $3.73. Sees FY14 revenue growth in the 35% range, consensus $116.72B. The company says "Adjusted operating margin is expected to decline in the high-teens basis points range due to the onboarding of significant new lower margin business and growth in brand pharmaceutical business with our large customers. We expect free cash flow to be in the high end of the range of $500 to $700 million, with capital expenditures in the $275 million range, and to spend approximately $500 million in share repurchases, subject to market conditions."
07:02 EDTABCAmerisourceBergen reports Q3 continuing ops EPS $1.01, consensus 92c
Reports Q3 revenue $30.35B, consensus $29.25B.
06:40 EDTPHMPulteGroup reports Q2 backlog value $2.8B
Subscribe for More Information
06:38 EDTPHMPulteGroup reports Q2 EPS 11c, may not compare to consensus 25c
Reports Q2 revenue $1.29B, consensus $1.33B. Q2 net income was $42M, or 11c per share, after pretax charges of $88M, or 14c per share, for insurance reserves and office relocation costs. Net income for the second quarter reflects $26M, or 7c per share, of income tax expense.
July 23, 2014
10:02 EDTDRHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:02 EDTDRHOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: 21st Century Fox (FOXA) downgraded to Market Perform from Outperform at Cowen... Brinker (EAT) downgraded to Sector Perform from Outperform at RBC Capital... Cubist (CBST) downgraded to Market Perform from Outperform at JMP Securities... DiamondRock (DRH) downgraded to Neutral from Outperform at RW Baird... DuPont (DD) downgraded to Neutral from Overweight at JPMorgan... FirstMerit (FMER) downgraded to Neutral from Overweight at JPMorgan... Helmerich & Payne (HP) downgraded to Accumulate from Buy at Tudor Pickering... Hexcel (HXL) downgraded to Hold from Buy at Canaccord... Juniper (JNPR) downgraded to Neutral from Buy at BofA/Merrill... King Digital (KING) downgraded at BofA/Merrill... Lexmark (LXK) downgraded at Raymond James... McDonald's (MCD) downgraded at RW Baird... Mead Johnson (MJN) downgraded to Outperform from Buy at CLSA... National Oilwell (NOV) downgraded to Accumulate from Buy at Tudor Pickering... Nintendo (NTDOY) downgraded to Hold from Buy at Jefferies... Raytheon (RTN) downgraded to Market Perform from Outperform at Bernstein... Targa Resources (TRGP) downgraded to Accumulate from Buy at Global Hunter... Time Warner (TWX) downgraded to Market Perform from Outperform at Cowen... Timmins Gold (TGD) downgraded to Market Perform from Outperform at Cowen... United Technologies (UTX) downgraded to Market Perform from Outperform at Wells Fargo... Viacom (VIAB) downgraded to Market Perform from Outperform at Cowen... Xilinx (XLNX) downgraded at BMO Capital.
08:40 EDTDRHDiamondRock initiated with a Neutral at ISI Group
Target $13.
07:21 EDTDRHDiamondRock downgraded to Neutral from Outperform at RW Baird
Baird downgraded DiamondRock to Neutral based on full valuation, dependence on outsized growth at the Lexington Hotel and exposure to New York City and Chicago. Price target raised to $14 from $13.
July 22, 2014
10:01 EDTSNTASynta Pharmaceuticals strength a selling opportunity, says Stifel
Subscribe for More Information
09:07 EDTSNTASynta Pharmaceuticals data positive, says JMP Securities
JMP Securities believes that early top-line data indicates Synta's ganetespib plus current standard of care, low-dose Ara-C provide clinical benefit in high-risk elderly patients with newly diagnosed AML and MDS. The firm says the results increase its confidence in a positive GALAXY-2 outcome in NSCLC and broad applicability of ganetespib across a variety of tumor types. It keeps an Outperform rating on the stock.
06:43 EDTAIGMalaysia Airlines incidents rattle insurance market, NY Times says
Subscribe for More Information
July 21, 2014
16:32 EDTSNTASynta Pharmaceuticals advances ganetespib into Phase 3 extension of AML LI-1
Synta Pharmaceuticals announced the advancement of ganetespib into the Phase 3 extension of the AML LI-1 trial. AML LI-1 is a multicenter, randomized Phase 2/3 clinical study evaluating several novel treatment regimens, including the combination of ganetespib with low dose cytarabine, in newly diagnosed elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome who are not eligible for intensive chemotherapy. Ganetespib is a next-generation inhibitor of the chaperone protein Hsp90, which is critical for the activation and stability of numerous proteins that drive cancer growth and proliferation. Ganetespib has been studied in over 1000 patients to date. Advancement into the Phase 3 extension follows an interim analysis of results from 50 patients who received the ganetespib-cytarabine combination in the Phase 2 portion of the trial. The primary efficacy outcome in Phase 2 was rate of complete response. Per protocol, the Phase 3 extension will include an interim futility analysis and enroll approximately 200 patients in the ganetespib-cytarabine and the cytarabine alone arms, for a total of approximately 400 patients. The primary efficacy endpoint for the Phase 3 extension will include overall survival. The Company is currently in discussion with study investigators, and anticipates providing additional details, including the timing of study milestones, as they become formalized. The AML LI-1 trial is the first of three multicenter, randomized studies supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK to include a ganetespib treatment arm. AML LI-1 is being conducted under the auspices of the UKs National Cancer Research Institute Haematological Oncology Study Group, with investigators in Denmark, France, New Zealand, and the UK, and under the sponsorship of Cardiff University, UK. The other two studies, to be initiated later this year, are the AML-18 trial, evaluating ganetespib with standard DA in patients over 60 years old who can tolerate intensive chemotherapy, and the AML-19 trial, evaluating ganetespib in combination with conventional chemotherapy in younger patients with AML.
07:29 EDTAIGAIG settlement with BofA takes crisis claw back total up to $2B, FT says
Subscribe for More Information
07:15 EDTMSIO'Reilly to hold a conference
Subscribe for More Information
July 17, 2014
11:12 EDTNWBOOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTAIGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:49 EDTAIGAIG initiated with an Outperform at RBC Capital
Target $64.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use